Clinical trials: Response Inhibition
P-glycoprotein, Healthy Volunteers
A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers
The purpose of this single-dose, open-label, sequential, three-period study in 15 healthy subjects was to assess the influence of P-glycoprotein inhibition and simultaneous CYP3A4 and P-glycoprotein induction on lenvatinib…
- Trial name
- NCT02199392
- Testing
- Lenvatinib
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Paroxysmal Nocturnal Hemoglobinuria
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
This study will enroll participants aged 12 years or older with a body weight ≥ 40 kilograms (kg) diagnosed with PNH who have not been previously treated with complement inhibitor therapy.
- Trial name
- COMMODORE 3 (NCT04654468)
- Testing
- Crovalimab
- Where
- 5 sites in China
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Healthy
Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine
Study to investigate the effect of cytochrome P 450 3A4 inhibition by itraconazole on the single dose pharmacokinetics of cilobradine
- Trial name
- NCT02264041
- Testing
- Cilobradine, low dose, Cilobradine, high dose, Itraconazole
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Drug Interaction
Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite
This is a single center, open-label, fixed sequence, drug-drug interaction (DDI) study in healthy subjects.
- Trial name
- NCT04902105
- Testing
- ecopipam HCL, Mefenamic acid, Divalproex Sodium ER
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Platelet Inhibition
A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin
The primary hypothesis of this study is that concomitant multiple-dose administration of PN 400 does not interfere with the platelet inhibitory effects of enteric-coated low-dose aspirin (81 mg), as measured by serum thromboxane…
- Trial name
- NCT01094483
- Testing
- PN400, ASA
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition
The study is a single-center, Phase-1, open-label, one-sequence, two-treatment period, cross-over, DDI study designed to investigate the effects of rilzabrutinib on the PK of digoxin (as P-gp substrate) and of rosuvastatin (as…
- Trial name
- NCT07855250
- Testing
- Rilzabrutinib, Rosuvastatin, Digoxin
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sanofi
Drug Drug Interaction
A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers
An open-label, non-randomized, 2-arm, 2-period fixed sequence phase 1 study to evaluate the potential inhibition of nitisinone on cytochrome P450 2C9, 2D6, and 2E1 and the organic anion transporters OAT1 and OAT3 in healthy…
- Trial name
- NCT03103568
- Testing
- Nitisinone in Arm A, Tolbutamide, Metoprolol
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Swedish Orphan Biovitrum
Ovulation Inhibition
Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens
The aim of the study is to investigate the ovulation inhibition of two 4-phasic oral contraceptive regimens.
- Trial name
- NCT00805415
- Testing
- EV/DNG (Qlaira, BAY86-5027, SH T00658K), EV/DNG (SH T00658L)
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers
Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants
To determine the time-dependent inhibition potential of repeated doses of oral vonoprazan on the pharmacokinetics (PK) of a single oral dose of midazolam, a sensitive cytochrome P450 3A4 (CYP3A4) substrate, in healthy…
- Trial name
- NCT04545944
- Testing
- Vonoprazan, Midazolam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Drug-Drug Interaction
A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate
This phase I open label study is conducted to assess the potential pharmacokinetic interaction of Raxone® with midazolam in healthy male volunteers
- Trial name
- NCT02887443
- Testing
- Raxone (idebenone 150 mg), Midazolam 2,5 mg
- Where
- France
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Santhera Pharmaceuticals
Breast Cancer
A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors
The aim of this study was to evaluate patient profiles, treatment patterns, and outcomes of hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (mBC) patients treated…
- Trial name
- NCT07512063
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
HR+ HER2- Breast Cancer
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants…
- Trial name
- NCT07558733
- Testing
- Serabelisib, Sapanisertib, Fulvestrant
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Faeth Therapeutics
Superficial Esophageal Cancer
Human (Autologous) Oral Mucosal Cell Sheet Transplantation After ESD in Patients With Superficial Esophageal Cancer
The purpose of this study is to evaluate the efficacy and safety of esophageal epithelial regenerative treatment by the transplantation of the product, CLS2702C, to the esophageal wound site after extensive ESD for superficial…
- Trial name
- NCT02866019
- Testing
- CLS2702C/CLS2702D
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- CellSeed Inc.
Atopic Dermatitis Eczema
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
This was a Phase 3, 4-week, double-blind study to assess the safety and efficacy of ARQ-151 cream compared to vehicle cream applied once daily (qd) for 4 weeks in children 2 to 5 years of age with atopic dermatitis (AD).
- Trial name
- NCT04845620
- Testing
- Roflumilast Cream 0.05%, Vehicle Cream
- Where
- 76 sites in United States, Canada
- Volunteers
- 652 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Myocardial Infarction, Cardiovascular Diseases
Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]
The purpose of this study is to determine whether KAI-9803 is safe and effective in reducing infarct size in subjects with ST elevation myocardial infarction (heart attack) undergoing a percutaneous coronary intervention (PCI).
- Conditions
- Myocardial Infarction, Cardiovascular Diseases, Pathologic Processes
- Trial name
- PROTECTION AMI (NCT00785954)
- Testing
- KAI-9803
- Where
- 126 sites in United States, Australia and 16 more
- Volunteers
- 1,180 people
- Sponsor
- KAI Pharmaceuticals
Dyslipidemia
Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)
This retrospective study evaluates the effectiveness and safety of ezetimibe plus statin or ezetimibe plus fenofibrate in dyslipidemic patients that were treated with these dual inhibition lipid lowering regimens as part of their…
- Trial name
- NCT00726856
- Testing
- Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate
- Volunteers
- 1,200 people
- Sponsor
- Organon and Co
Endometrial Cancer
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
- Trial name
- NCT06463028
- Testing
- Sapanisertib, Serabelisib, Paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- Faeth Therapeutics
Stage IV Melanoma, Metastatic Melanoma
Immunotherapy Study for Patients With Stage IV Melanoma
The purpose of this study is to examine the effectiveness of immune checkpoint inhibitors (drugs called ipilimumab, nivolumab, or pembrolizumab), either given alone, or in combination with the experimental immunotherapy drug…
- Trial name
- NCT02054520
- Testing
- HyperAcute®-Melanoma (HAM) Immunotherapy, Ipilimumab, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- NewLink Genetics Corporation
Acute Myeloid Leukemia
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
The purpose of this study is to determine the effectiveness of tipifarnib in patients aged 70 or more with acute myeloid leukemia. Tipifarnib belongs to a class of drugs called Farnesyl Transferase Inhibitors (FTI).
- Trial name
- NCT00093990
- Testing
- Tipifarnib;Zarnestra; R115777
- Volunteers
- 457 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Seasonal Allergic Rhinitis
Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen
This study will assess the effects of Imatinib on allergic inflammation following repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to Timothy grass pollen.
- Trial name
- NCT00426179
- Testing
- Imatinib
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Novartis